750 related articles for article (PubMed ID: 25713909)
1. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
[TBL] [Abstract][Full Text] [Related]
2. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
5. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome.
Wu TJ; Chan KM; Chou HS; Lee CF; Wu TH; Chen TC; Yeh CT; Lee WC
Ann Surg Oncol; 2013 Oct; 20(11):3582-90. PubMed ID: 23760589
[TBL] [Abstract][Full Text] [Related]
8. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.
Yang T; Lu JH; Zhai J; Lin C; Yang GS; Zhao RH; Shen F; Wu MC
Eur J Surg Oncol; 2012 Aug; 38(8):683-91. PubMed ID: 22621971
[TBL] [Abstract][Full Text] [Related]
9. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
11. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.
Sohn W; Paik YH; Kim JM; Kwon CH; Joh JW; Cho JY; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Ann Surg Oncol; 2014 Jul; 21(7):2429-35. PubMed ID: 24619495
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
13. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
Chen JD; Yang HI; Iloeje UH; You SL; Lu SN; Wang LY; Su J; Sun CA; Liaw YF; Chen CJ;
Gastroenterology; 2010 May; 138(5):1747-54. PubMed ID: 20114048
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma recurrence is an independent risk factor for HB recurrence after liver transplantation.
Gao PJ; Gao J; Li Z; Hu ZP; Zhu JY
Hepatogastroenterology; 2014 Sep; 61(134):1523-8. PubMed ID: 25436336
[TBL] [Abstract][Full Text] [Related]
15. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
[TBL] [Abstract][Full Text] [Related]
16. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence.
Li MR; Chen GH; Cai CJ; Wang GY; Zhao H
Digestion; 2011; 84(2):134-41. PubMed ID: 21502763
[TBL] [Abstract][Full Text] [Related]
17. Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma.
An HJ; Jang JW; Bae SH; Choi JY; Cho SH; Yoon SK; Han JY; Lee KH; Kim DG; Jung ES
J Gastroenterol Hepatol; 2010 Dec; 25(12):1876-82. PubMed ID: 21092000
[TBL] [Abstract][Full Text] [Related]
18. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
[TBL] [Abstract][Full Text] [Related]
19. Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.
Ijichi H; Yoshizumi T; Ikegami T; Soejima Y; Ikeda T; Kawanaka H; Uchiyama H; Yamashita Y; Morita M; Oki E; Mimori K; Sugimachi K; Saeki H; Watanabe M; Shirabe K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):376-82. PubMed ID: 24511669
[TBL] [Abstract][Full Text] [Related]
20. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
